Description

D. C. Wiley & J. J. Skehel. (1987) The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem, 56, 365-394.

**D. C. Wiley & J. J. Skehel. (1987) The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem, 56, 365-394.**

—

When you hear the word *influenza*, images of feverish patients, seasonal outbreaks, and global pandemics often come to mind. Yet, behind every flu episode lies a microscopic marvel: the hemagglutinin (HA) membrane glycoprotein. The landmark 1987 review by D. C. Wiley and J. J. Skehel remains a cornerstone for scientists, clinicians, and anyone curious about how this viral protein drives infection, immunity, and vaccine design. In this post we’ll unpack the key insights from that seminal work, explain why HA still matters today, and explore how modern research builds on those foundations.

### The architectural blueprint of hemagglutinin

Wiley and Skehel were the first to describe HA as a **trimeric spike** protruding from the influenza virus envelope. Each monomer consists of two subunits—HA1 and HA2—produced by proteolytic cleavage of a single precursor (HA0). The HA1 region forms the globular head that binds sialic‑acid receptors on host cells, while HA2 contains the **fusion peptide** that drives membrane merging. Their detailed electron‑microscopy images revealed a “crown‑like” arrangement, a visual that still appears in textbooks and vaccine illustrations.

### How HA orchestrates viral entry

The review highlighted a two‑step mechanism that remains the textbook definition of influenza infection:

1. **Receptor binding** – HA1’s receptor‑binding site (RBS) recognizes α‑2,6‑linked sialic acids in the human upper respiratory tract (or α‑2,3‑linked in avian species). This specificity determines host range and zoonotic potential.
2. **pH‑triggered fusion** – After endocytosis, the acidic environment of the endosome induces a dramatic conformational change in HA2. The fusion peptide inserts into the endosomal membrane, pulling the viral and host membranes together to release the viral RNA into the cytoplasm.

Understanding these steps clarified why **mutations in the HA gene** can alter transmissibility, pathogenicity, and resistance to antiviral drugs.

### HA as the primary target of the immune system

Wiley and Skehel emphasized that HA is the **immunodominant antigen** of influenza. Antibodies that block the RBS prevent virus attachment, while those that bind the stem region (HA2) can inhibit the fusion process. This dual vulnerability explains why seasonal flu vaccines focus on HA: they aim to elicit neutralizing antibodies that recognize the head, and increasingly, the more conserved stem.

### Implications for vaccine development

The 1987 review set the stage for modern **universal flu vaccine** strategies. By mapping the conserved epitopes in HA2, researchers now design “stem‑focused” immunogens that could protect against multiple influenza subtypes. The paper also underscored the importance of **glycosylation**—the addition of sugar moieties to HA—that can shield antigenic sites from immune detection, a factor vaccine developers must consider when selecting strain candidates.

### Continuing relevance in the age of COVID‑19

Even two decades after its publication, the Wiley & Skehel article is frequently cited in contemporary literature on **viral entry mechanisms**, **antibody escape**, and **structure‑guided drug design**. Its meticulous description of HA’s structure–function relationship informs computational modeling, cryo‑EM studies, and the design of HA‑based **nanoparticle vaccines** now being tested in clinical trials.

### Takeaway: Why you should care about hemagglutinin

– **Public health:** HA determines which influenza strains can jump from birds or pigs to humans, influencing pandemic risk assessments.
– **Vaccine efficacy:** Seasonal flu shots are updated each year based on HA antigenic drift; understanding HA helps explain why vaccine mismatches occur.
– **Therapeutic innovation:** Small‑molecule inhibitors that lock HA in its pre‑fusion conformation are a promising class of antivirals under investigation.

In short, the 1987 review by Wiley and Skehel does more than recount a protein’s anatomy; it provides a roadmap for combating one of humanity’s most persistent viral foes. Whether you’re a researcher, a healthcare professional, or simply a curious reader, appreciating the **structure and function of the hemagglutinin membrane glycoprotein** offers a deeper grasp of influenza biology and the ongoing quest for a universal flu vaccine.

—

*Keywords: influenza virus, hemagglutinin, HA structure, viral glycoprotein, vaccine design, universal flu vaccine, viral entry, receptor binding, membrane fusion, antigenic drift, immune response, Wiley & Skehel 1987.*